Inetetamab in Combination With Pyrotinib in HER2 Mutant or Amplified Advanced Non-small Cell Lung Cancer
Status:
Recruiting
Trial end date:
2025-02-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1, open-label study to evaluate the safety and the efficacy of inetetamab in
combination with pyrotinib in patients in HER2 mutant or amplified patients with advanced
non-small cell lung cancer